MRC Primary Thrombocythaemia-1

Lead Research Organisation: University of Cambridge
Department Name: Haematology

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
 
Guideline Title Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis
Description National and International Clinical guidelines
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Description CRUK CTAAC
Amount £462,865 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2008 
End 04/2013
 
Description CRUK Programme Grant
Amount £240,279 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2011 
End 09/2014
 
Description KKLF grant
Amount £1,632,075 (GBP)
Organisation The Kay Kendall Leukaemia Fund 
Sector Academic/University
Country United Kingdom
Start 09/2009 
End 08/2012
 
Description LRF Programme Grant
Amount £2,230,206 (GBP)
Organisation Leukaemia and Lymphoma Research 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2008 
End 03/2013
 
Description Specialized Center of Research/The Leukemia & Lymphoma Society
Amount £2,300,000 (GBP)
Organisation The Leukemia & Lymphoma Society 
Sector Charity/Non Profit
Country United States
Start 10/2011 
End 09/2016
 
Description Specialized Center of Research/The Leukemia & Lymphoma Society, USA
Amount £2,300,000 (GBP)
Organisation The Leukemia & Lymphoma Society 
Sector Charity/Non Profit
Country United States
Start 10/2006 
End 09/2012
 
Title Diagnostic test and mouse model 
Description Diagnostic test and mouse model 
Type Of Material Model of mechanisms or symptoms - mammalian in vivo 
Year Produced 2010 
Provided To Others? Yes  
Impact Discovery of JAK2 mutation has resulted in a new molecular classification of the myeloproliferative neoplasms. We have also generated a mouse model of the disease. We have developed several diagnostic tests (for JAK2 mutation and other mutations) which are now in routine diagnostic use in out regional diagnostic service 
 
Description Management and pathogenesis of myeloproliferative neoplasms 
Organisation Belfast City Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution Leadership of clinical trials. Director of LLR research programme on myeloproliferative neoplasms.
Collaborator Contribution Clinical trial and laboratory researchClinical trialClinical trial
Impact Please see section 1.1. In addition: Harrison et al, ENJM 2005 Baxter et al, Lancet 2005 Campbell et al, Lancet 2005 Chen et al, Cancer Cell 2010
 
Description Management and pathogenesis of myeloproliferative neoplasms 
Organisation St Thomas' Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution Leadership of clinical trials. Director of LLR research programme on myeloproliferative neoplasms.
Collaborator Contribution Clinical trial and laboratory researchClinical trialClinical trial
Impact Please see section 1.1. In addition: Harrison et al, ENJM 2005 Baxter et al, Lancet 2005 Campbell et al, Lancet 2005 Chen et al, Cancer Cell 2010
 
Description Management and pathogenesis of myeloproliferative neoplasms 
Organisation The Wellcome Trust Sanger Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Leadership of clinical trials. Director of LLR research programme on myeloproliferative neoplasms.
Collaborator Contribution Clinical trial and laboratory researchClinical trialClinical trial
Impact Please see section 1.1. In addition: Harrison et al, ENJM 2005 Baxter et al, Lancet 2005 Campbell et al, Lancet 2005 Chen et al, Cancer Cell 2010
 
Description Recent advances in the myeloproliferative neoplasms 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Participants in your research and patient groups
Results and Impact 50 patients attended a talk on recent advances in the myeloproliferative neoplasms

None
Year(s) Of Engagement Activity 2007,2009,2011,2012,2013